 |
 | Home | Contact Us | FAQ | Search & Site Map | Link to Us |
 | Sign In | Join | Other 45 Sites in Network |
Medical Forum / Diseases and Disorders / Lupus / August 2008Porphyria and Vitamin E and Alpha-lipoic Acid
Secunder prevention with alpha-lipoic acid and vitamin E in porphyria cutanea tarda patients Z Gastroenterol 2008; 46 E Székely 1, K Szentmihályi 2, M Bor 1, Á Pusztai 1, T Kurucz 3, Z Pallai 3, A Blázovics 4 1 1st National Medical Center, Budapest, Hungarian Porphyria Center 2 2nd Chemical Research Center, Hugarian Academy of Sciences 3 3rd Diachem Kft, Budapest 4 4th Semmelweis University 2nd Department of Medicine Budapest, Hungary Introduction: Decreased activity of uroporphyrinogen decarboxylase enzyme cause porphyria cutanea tarda (PCT). The activity of the cytochrome P450 lA2 appears to be another impotant etiological factor in PCT. Abnormal iron metabolism produced oxidative radicals by reactive intracellular iron. Vitamin E and alpha-lipoic acid are a potent antioxidant combination with the protective effects against lipid peroxidation, oxidative stress, inflammation, infection, and protein carbonyl formation. Aim: We investigated the effect of vitamin E and alpha-lipoic acid on porphyrin concentration, iron metabolism and redox homeostasis. Patients were treated with vitamin E (tocopherolum aceticum 200mg „Bioextra“) capsule for 8 weeks and alpha-lipoic acid (Thiogamma 600R) capsule for 8 weeks. We analysed the data of 18 PCT male patients and 10 controls of Caucasian origin. Methods: Rutin laboratory parameters were measured (AST, ALT, GGT, HDL- CHOL, LDL-CHOL, CHOL, Tg, glucose, HbA1c, iron, transferrin and ferritin) with Roche/Hitachi MODULAR equipment. H-donor activity, reducing power, SOD and GSH-Px was measured by spectrophotometry and chemiluminescent intensity of plasma and erythrocytes were measured with LB 9501 luminometer. Results: Significant difference was found in urine-UP level after treatment with both antioxidant. AST, ALT, GGT were changed more beneficial as well. Plasma and erythrocyte chemiluminescent intensity was significantly higher in PCT patients compared to the control. SOD and GSH-Px concentrations were significantly lower in PCT patients than in the controls. These data indicate that the antioxidant status of PCT patients has changed. Conclusion: Per os treatment with vitamin E (200mg/day) and alpha- lipoic acid (600mg/day) over 8 weeks is safe and effective in reducing symptoms of PCT and general feeling of patients have improved. The study was supported by the ETT 012/2006 Ministry of Health, Social and Family Affairs. DOI: 10.1055/s-2008-1079707 Who loves ya. Tom Jesus Was A Vegetarian! http://tinyurl.com/634q5a Man Is A Herbivore! http://tinyurl.com/4rq595 DEAD PEOPLE WALKING http://tinyurl.com/zk9fk On Aug 23, 9:55 am, "ironjust...@aol.com" <ironjust...@aol.com> wrote: alpha-lipoic acid and vitamin E << Alpha-lipoic acid is an iron chelator. Vitamin E 'stands in' for vitamin C and visa versa. It seems the targeting of this iron might be the .. key. This problem lies with the .. increased iron .. as evidenced by the HIGH levels of iron required to PRODUCE porphyria in this study. "Ascorbate suppresses hepatic URO accumulation at low, but not high hepatic iron levels " Effect of iron and ascorbate on uroporphyria in ascorbate-requiring mice as a model for porphyria cutanea tarda. Gorman N, Zaharia A, Trask HS, Szakacs JG, Jacobs NJ, Jacobs JM, Balestra D, Sinclair JF, Sinclair PR Hepatology. 2006 Dec 22; 45(1): 187-194 Excess hepatic iron is known to enhance both porphyria cutanea tarda (PCT) and experimental uroporphyria. Since previous studies have suggested a role for ascorbate (AA) in suppressing uroporphyria in AA-requiring rats (in the absence of excess iron), the present study investigated whether AA could suppress uroporphyria produced by excess hepatic iron. Hepatic URO accumulation was produced in AA-requiring Gulo(-/-) mice by treatment with 3,3',4,4',5-pentachlorbiphenyl, an inducer of CYP1A2, and 5-aminolevulinic acid. Mice were administered either sufficient AA (1000 ppm) in the drinking water to maintain near normal hepatic AA levels or a lower intake (75 ppm) that resulted in 70 % lower hepatic AA levels. The higher AA intake suppressed hepatic URO accumulation in the absence of administered iron, but not when iron dextran (300-500 mg Fe/kg) was administered. This effect of iron was not due to hepatic AA depletion since hepatic AA content was not decreased. The effect of iron to prevent AA suppression of hepatic URO accumulation was not observed until a high hepatic iron threshold was exceeded. At both low and high AA intakes, hepatic malondialdehyde (MDA), an indicator of oxidative stress, was increased three-fold by high doses of iron dextran. MDA was considerably increased even at low iron dextran doses, but without any increase in URO accumulation. The level of hepatic CYP1A2 was unaffected by either AA intake. Conclusion: In this mouse model of PCT, AA suppresses hepatic URO accumulation at low, but not high hepatic iron levels. These results may have implications for the management of PCT. (HEPATOLOGY 2007;45:187-194.). 10.1002/hep.21474 Who loves ya. Tom Jesus Was A Vegetarian! http://tinyurl.com/634q5a Man Is A Herbivore! http://tinyurl.com/4rq595 DEAD PEOPLE WALKING http://tinyurl.com/zk9fk > Secunder prevention with alpha-lipoic acid and vitamin E in porphyria > cutanea tarda patients [quoted text clipped - 56 lines] > > DEAD PEOPLE WALKINGhttp://tinyurl.com/zk9fk |
Reply to this Message |
 Sign In
 Join
 My Latest Posts My Monitored Threads My Blog My Photo Gallery My Profile My Homepage Start New Thread Enable EMail Alerts Rate this Thread
|
©2009 Advenet LLC Privacy Policy - Terms of Use
This website includes both content owned or controlled by Advenet as well as content owned or controlled by third parties.